Teacher Retirement System of Texas Makes New $253,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL)

Teacher Retirement System of Texas acquired a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,475 shares of the company’s stock, valued at approximately $253,000.

A number of other institutional investors have also modified their holdings of CSTL. China Universal Asset Management Co. Ltd. grew its stake in Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock worth $158,000 after acquiring an additional 604 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in shares of Castle Biosciences by 3.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company’s stock worth $690,000 after purchasing an additional 845 shares during the last quarter. Truist Financial Corp grew its position in shares of Castle Biosciences by 4.6% in the fourth quarter. Truist Financial Corp now owns 21,303 shares of the company’s stock valued at $568,000 after purchasing an additional 928 shares during the period. Bailard Inc. increased its stake in Castle Biosciences by 12.5% in the fourth quarter. Bailard Inc. now owns 9,900 shares of the company’s stock valued at $264,000 after purchasing an additional 1,100 shares during the last quarter. Finally, R Squared Ltd purchased a new position in Castle Biosciences during the fourth quarter worth about $42,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

CSTL has been the subject of several recent analyst reports. Guggenheim set a $30.00 price target on Castle Biosciences and gave the company a “buy” rating in a report on Friday. Robert W. Baird raised their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Finally, Stephens reaffirmed an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $38.75.

Insider Buying and Selling at Castle Biosciences

In other news, insider Derek J. Maetzold sold 986 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.03, for a total value of $27,637.58. Following the completion of the sale, the insider now owns 80,818 shares in the company, valued at approximately $2,265,328.54. This trade represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the transaction, the director now directly owns 1,425 shares in the company, valued at $41,524.50. This trade represents a 84.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,440 shares of company stock valued at $1,081,079 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Stock Down 1.2 %

Shares of NASDAQ:CSTL opened at $19.78 on Wednesday. The stock has a 50-day simple moving average of $23.96 and a 200-day simple moving average of $27.82. The stock has a market capitalization of $553.98 million, a P/E ratio of 98.90 and a beta of 0.98. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.